Almirall (ES:ALM) has released an update. Almirall, S.A. is set to present and discuss its financial results for the first nine months of 2024 via a webcast with analysts and institutional investors.

Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking ...

Almirall (BME: ALM), the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 ...

Almirall has put patients’ friends and family at the heart of its activities for the 2024 World Psoriasis Day, ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

The third edition of ImmunoSkin underscored Almirall’s commitment to advancing the scientific understanding of skin and its diseases, and to pioneering innovation in medical dermatology and ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

With the addition of this treatment, Almirall enhances its European medical dermatology portfolio and reaffirms its commitment to people living with skin infections and dermatologists by providing ...

BARCELONA, Spain, October 15, 2024--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology announced today the successful completion of the ...

Kikuchi–Fujimoto disease (KFD), histiocytic necrotising lymphadenitis, is a benign and self-limiting disease characterised ...